• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Palatin’s LeuTech begins phase III trials

Article

Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium

Biopharmaceutical firm Palatin Technologies of Princeton, NJ, announced that it will begin multisite phase III trials next month for LeuTech, its radiopharmaceutical for infection imaging. LeuTech consists of a monoclonal antibody labeled with technetium for imaging such infections as appendicitis and osteomyelitis. Palatin expects to complete phase III trials in the first part of 1999.

The firm is also working on peptide-based therapeutics and imaging agents such as PT5, a cancer therapeutic; PT11, an infection imaging agent based on the company's metal ion-induced distinctive array of structures (MIDAS) metallopeptide technology; and PT14, a therapeutic agent for sexual dysfunction.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.